Zai Lab Ltd
ZLAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001704292
In the last 90 days, Zai Lab Ltd insiders filed 1 open-market purchase and 1 sale; 93 institutions reported holding it in 13F filings for Q2 2026, worth $819.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:57 PM ET
Revenue flow, Q3 FY2026
Where the revenue went in Q3 FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for Q3 FY2026: $46.1M (42.6% of revenue).
Income statement
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 5, 2026 | Aug 6, 2026 | May 7, 2026 | Feb 26, 2026 | Nov 6, 2025 | Aug 7, 2025 | May 8, 2025 | Feb 27, 2025 |
| Revenue | $108.2M | $106.3M | $99.6M | $127.6M† | $116.1M | $110.0M | $106.5M | $109.1M† |
| Cost of revenue | $51.3M | $48.2M | $38.3M | $62.3M† | $46.8M | $43.0M | $38.5M | $41.8M† |
| Research and development | $49.8M | $61.8M | $65.6M | $61.6M† | $47.9M | $50.6M | $60.7M | $52.3M† |
| Selling, general and administrative | $70.1M | $72.9M | $65.1M | $73.0M† | $70.1M | $71.0M | $63.4M | $82.6M† |
| Operating income | -$63.0M | -$76.5M | -$69.4M | -$69.4M† | -$48.8M | -$54.9M | -$56.3M | -$67.9M† |
| Income tax | -$1.87M | -$1.02M | $1.44M | -$2.93M† | $0 | $0 | $0 | $0† |
| Net income | -$46.1M | -$50.8M | -$51.0M | -$50.4M† | -$36.0M | -$40.7M | -$48.4M | -$81.7M† |
| EPS, basic | $-0.04 | $-0.05 | $-0.05 | – | $-0.03 | $-0.04 | $-0.04 | – |
| EPS, diluted | $-0.04 | $-0.05 | $-0.05 | – | $-0.03 | $-0.04 | $-0.04 | – |
| Weighted shares, basic | 1.12B | 1.12B | 1.11B | – | 1.10B | 1.09B | 1.08B | – |
| Weighted shares, diluted | 1.12B | 1.12B | 1.11B | – | 1.10B | 1.09B | 1.08B | – |
| Margins and growth | ||||||||
| Operating margin | -58.2% | -71.9% | -69.7% | -54.4% | -42.1% | -49.9% | -52.9% | -62.2% |
| Net margin | -42.6% | -47.8% | -51.2% | -39.5% | -31.0% | -37.0% | -45.5% | -74.9% |
| Revenue growth, year over year | −6.8% | −3.3% | −6.5% | +17.0% | +13.5% | +9.4% | +22.2% | +65.7% |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 5, 2026 | Aug 6, 2026 | May 7, 2026 | Feb 26, 2026 | Nov 6, 2025 | Aug 7, 2025 | May 8, 2025 | Feb 27, 2025 |
| Cash and equivalents | $549.7M | $607.5M | $651.3M | $679.6M | $717.2M | $732.2M | $757.3M | $449.7M |
| Short-term investments | $10.0M | $10.0M | $10.0M | $10.0M | $0 | $0 | $0 | $330.0M |
| Accounts receivable | $65.3M | $69.6M | $54.1M | $106.1M | $85.4M | $88.5M | $76.6M | $85.2M |
| Inventory | $85.3M | $90.9M | $86.0M | $74.7M | $67.1M | $61.7M | $53.1M | $39.9M |
| Total current assets | $864.4M | $914.0M | $944.7M | $1.02B | $1.03B | $1.03B | $1.04B | $1.05B |
| Property, plant and equipment | $46.1M | $46.4M | $47.1M | $47.4M | $48.9M | $50.2M | $49.7M | $48.0M |
| Intangible assets | $85.3M | $85.8M | $75.8M | $76.1M | $55.3M | $56.5M | $56.2M | $56.0M |
| Total assets | $1.02B | $1.07B | $1.10B | $1.17B | $1.16B | $1.16B | $1.17B | $1.19B |
| Accounts payable | $120.2M | $136.7M | $126.2M | $141.6M | $99.7M | $107.4M | $103.0M | $100.9M |
| Short-term debt | $252.4M | $238.1M | $213.8M | $204.5M | $203.0M | $174.5M | $173.4M | $131.7M |
| Total current liabilities | $424.2M | $428.6M | $393.0M | $416.2M | $359.8M | $331.5M | $319.8M | $299.4M |
| Total liabilities | $460.6M | $467.8M | $433.8M | $456.9M | $399.0M | $372.4M | $362.6M | $344.9M |
| Shareholders' equity | $563.3M | $607.0M | $662.0M | $715.5M | $759.9M | $791.7M | $810.8M | $840.9M |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q3 FY2026† | Q2 FY2026† | Q1 FY2026 | Q4 FY2025† | Q3 FY2025† | Q2 FY2025† | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 5, 2026 | Aug 6, 2026 | May 7, 2026 | Feb 26, 2026 | Nov 6, 2025 | Aug 7, 2025 | May 8, 2025 | Feb 27, 2025 |
| Operating cash flow | -$57.9M† | -$63.4M† | -$11.9M | -$26.0M† | -$32.0M† | -$31.0M† | -$61.7M | -$55.8M† |
| Capital expenditures | $947.0K† | $1.31M† | $1.20M | $677.0K† | $3.00M† | $2.88M† | $1.53M | $2.60M† |
| Free cash flow | -$58.8M | -$64.7M | -$13.1M | -$26.7M | -$35.0M | -$33.9M | -$63.2M | -$58.4M |
| Depreciation and amortization | $4.41M† | $4.17M† | $3.94M | $3.92M† | $3.90M† | $3.73M† | $3.46M | $3.03M† |
| Stock-based compensation | $11.0M† | $11.9M† | $13.5M | $15.9M† | $16.9M† | $17.0M† | $15.8M | $17.2M† |
| Investing cash flow | -$12.7M† | -$1.42M† | -$22.3M | -$11.3M† | -$4.05M† | -$2.92M† | $326.1M | -$347.8M† |
| Financing cash flow | $14.1M† | $18.7M† | $5.57M | -$430.0K† | $20.8M† | $8.85M† | $43.1M | $237.8M† |
| Net change in cash | -$57.9M† | -$43.8M† | -$28.3M | -$37.6M† | -$15.1M† | -$25.0M† | $307.6M | -$166.4M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 10.2% | 11.2% | 13.6% | 12.5% | 14.6% | 15.4% | 14.8% | 15.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.